RT Journal Article
T1 Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis
A1 Navarro-Compán, Victoria
A1 Navarro-Sarabia, Federico
K1 New targets
K1 Monoclonal antibodies
K1 Small molecules
K1 Rheumatoid arthritis
K1 Efficacy
K1 Safety
K1 Nuevos objetivos
K1 Anticuerpos monoclonales
K1 Moléculas pequeñas
K1 Artritis reumatoide
K1 Eficacia
K1 Seguridad
AB Biological therapies have been a major advance in RA treatment. However, remission or response is not achieved in allpatients. Therefore, new drugs seem necessary. Most recent trials have focused in the development of three different groups of molecules:those against commercialized targets but minimizing side effects or improving administration, others molecules against newtargets, and a third group including small molecules. Some of them have been shown to be clinically efficacious and safe in RA patients,including: two new anti-TNF􀁁 therapies (golimumab and certolizumab pegol), three anti-CD (ocrelizumab, ofatumumab and a SMIP),subcutaneous abatacept, anti-IL17 therapy, tasocitinib and fostamatinib disodium. Therefore, a wide spectrum of new RA therapeutics are promising, but more studies are necessary to confirm these results.
PB Libertas Academica
SN 1179-559X
YR 2011
FD 2011-07-15
LK http://hdl.handle.net/10668/505
UL http://hdl.handle.net/10668/505
LA en
NO Navarro-Compán V, Navarro-Sarabia F. Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis. Clinical Medicine Insights: Therapeutics 2011 3 (195-203)
DS RISalud
RD Apr 6, 2025